与罗斯马林酸相结合的塔克林减弱
Manyv Zheng1, Mingjuan Yang1, Xiaoqing Li2
1Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Phytochemical analysis : PCA
|July 31, 2025
概括
结合罗斯马林酸 (RA) 和塔克林 (TAC) 有效地治疗阿尔茨海默病 (AD),通过减少神经炎症和改善肝功能. 这种组合疗法增强了粉样蛋白斑块的微质清除,并减轻了AD小鼠模型中TAC诱导的肝损伤.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,全球发病率不断增加.
- 塔克林 (TAC) 是阿尔茨海默氏症早期治疗方法,由于严重的肝毒性而被取消.
- 罗斯马林酸 (RA) 具有神经保护性和肝脏保护性.
研究的目的:
- 调查罗斯马林酸 (RA) 和塔克林酸 (TAC) 对阿尔茨海默病 (AD) 的联合治疗潜力.
- 在小鼠模型中评估RA + TAC在减轻TAC诱导的肝毒性和增强AD干预方面的疗效.
- 评估RA+TAC对神经炎症,β-粉样蛋白 (Aβ) 斑块清除和AD中的微质功能的影响.
主要方法:
- 一个阿尔茨海默氏病 (AD) 鼠标模型是使用高剂量的d-银糖在4周的时间内进行的.
- 小鼠同时接受了不同剂量的罗斯马林酸 (RA) 和塔克林 (TAC) 治疗.
- 评估包括行为测试,生物化学测试 (抗氧化剂水平,肝酶),组织学分析和Aβ斑块,微质标记物 (TREM2,Iba-1,Arg-1) 和炎症通路 (TLR4,NF-κB) 的评估.
主要成果:
- 与单一治疗相比,联合治疗 (RA + TAC) 在改善AD症状方面表现出更高的疗效,其效果与RA剂量有积极的相关性.
- RA + TAC 治疗显著增强了抗氧化能力,减少了海马体损伤,改善了胆固醇系统,并降低了 Aβ 斑块负担.
- 组合疗法通过上调TREM2和将M1微质转移到M2表型来促进微质Aβ清除,同时还减少神经炎症标志物和缓解TAC诱导的肝损伤.
结论:
- 罗斯马林酸 (RA) 和塔克林 (TAC) 的联合使用显示出在缓解阿尔茨海默氏病 (AD) 病理方面具有显著的潜力.
- 这种组合疗法有效降低了与塔克林 (TAC) 相关的肝毒性.
- RA + TAC 是一个有前途的治疗策略,用于提高阿尔茨海默病 (AD) 治疗结果.
更多相关视频
10:33Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
1.4K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.8K
相关概念视频
01:24Cholinergic Antagonists: Pharmacokinetics
562
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
562
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
01:24Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
835
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
835
01:28Cholinergic Antagonists: Pharmacological Actions
1.2K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.2K
01:30Combined Effects of Drugs: Antagonism
9.3K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.3K